Düsseldorf University Hospital

Running trials

• Not yet recruiting

  A Study to Evaluate Clinical Benefit, Performance and Safety of Cochlear Implants in Adults

  NCT07338864· Source

• Recruiting

  Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy

  NCT07882797· Source

• Recruiting

  GRAnulomatous MAstitis REGistry Study

  NCT07422870· Source

• Not yet recruiting

  Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis

  NCT07577466· Source

• Not yet recruiting

  RELIEVE METAB Study

  NCT07555925· Source

• Not yet recruiting

  Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).

  2025-523672-23-00· Phase 2· Source

• Recruiting

  Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support

  NCT07655479· Source

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Source

• Recruiting

  Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

  NCT07273903· Source

• Active, not recruiting

  COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)

  NCT07455097· Source

• Recruiting

  NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

  NCT07365930· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Source

• Recruiting

  Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps

  NCT06765226· Source

• Recruiting

  Biological Determinants and Neural Compensation of Dysphagia in Parkinson's Disease

  NCT07299448· Source

• Recruiting

  Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

  NCT07264426· Source

• Enrolling by invitation

  Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)

  NCT06898086· Source

• Recruiting

  Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  NCT06780111· Phase 1/2· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  NCT06782373· Phase 2· Source

• Active, not recruiting

  FARAPULSE Workflow Assessment Registry

  NCT06656884· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Source

• Recruiting

  Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

  NCT06764706· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Source

• Recruiting

  Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer

  NCT06820333· Source

• Recruiting

  Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

  NCT07426991· Source

• Recruiting

  A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

  NCT06780150· Source

• Recruiting

  Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

  NCT06498349· Source

• Recruiting

  STIMPulseControl Ancillary Speech Study

  NCT06561919· Source

• Recruiting

  Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach

  NCT06501950· Source

• Recruiting

  Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

  NCT06122584· Phase 3· Source

• Recruiting

  Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer

  NCT06474806· Phase 2· Source

• Recruiting

  PROCARE - PROstate Cancer Real World Evidence Registry

  NCT06835218· Source

• Recruiting

  Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

  NCT06553625· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Source

• Active, not recruiting

  A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

  NCT06055725· Source

• Recruiting

  The ReTAVI Prospective Observational Registry

  NCT05601453· Source

• Recruiting

  The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

  NCT05427370· Source

• Not yet recruiting

  Mesopancreas Study in Pancreatic Cancer

  NCT05895214· Source

• Recruiting

  Home-based Gait and Balance Training in Patients With Movement Disorders

  NCT06617884· Source

• Recruiting

  DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device

  NCT05543447· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT05471843· Phase 1/2· Source

• Active, not recruiting

  TRICuspid Intervention in Heart Failure Trial

  NCT04634266· Source

Showing 50 of 83.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease7 recruiting
• Heart failure5 recruiting
• Prostate cancer5 recruiting
• Childhood cancers4 recruiting
• Coronary artery disease4 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Dystonia3 recruiting
• Essential tremor3 recruiting
• Multiple sclerosis3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Aortic stenosis2 recruiting
• Bladder cancer2 recruiting
• Colorectal cancer2 recruiting
• Pancreatic cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Brain aneurysm1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Ulcerative colitis1 recruiting
• Ventricular tachycardia1 recruiting

Researchers

• IEIrene Esposito
• TLTom Luedde

Closed trials

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· Source

• Terminated

  The RECOVER IV Trial

  NCT05506449· Source

• Completed

  Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia

  NCT05884528· Source

• Recruiting

  A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

  NCT05319730· Phase 1/2· Source

• Active, not recruiting

  An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma

  2022-501463-40-01· Phase 3· Source

• Completed

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· Phase 3· Source

• Terminated

  KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

  NCT06342960· Phase 1/2· Source

• Active, not recruiting

  A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

  NCT05490446· Phase 2· Source

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Source

• Completed

  A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

  NCT05342636· Phase 1/2· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Source

• Completed

  Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

  NCT04931771· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source

• Completed

  Combined Active Treatment in Type 2 Diabetes With NASH

  NCT04639414· Phase 4· Source

• Completed

  NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients

  NCT06688149· Source

• Completed

  REcanalization of Distal Cerebral Vessels in Acute Stroke Using ApeRio®

  NCT04479020· Source

• Terminated

  Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

  NCT04261777· Phase 3· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Triple-Negative Breast Cancer

  2022-500418-24-00· Phase 2/3· Source

• Terminated

  The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO

  NCT04029233· Source

• Completed

  PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

  NCT03996772· Phase 3· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· Phase 3· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Completed

  RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

  NCT03520946· Phase 3· Source

• Completed

  A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

  NCT03745287· Phase 2/3· Source

• Completed

  Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

  NCT03635567· Phase 3· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Source

• Completed

  A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

  NCT03573310· Phase 1· Source

• Completed

  FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System

  NCT03417011· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· Phase 3· Source

• Completed

  A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation

  NCT02444338· Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Phase 3· Source

• Completed

  Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

  NCT01644110· Phase 1/2· Source

• Completed

  SD01 Master Study (Safety and Efficacy Study)

  NCT01836497· Source

• Completed

  Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

  NCT01228331· Phase 2/3· Source

Trial sites

• Universitatsklinikum Dusseldorf0 trials
• Cardiovascular Centre - University Hospital Düsseldorf0 trials
• Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Duesseldorf1 trial
• Düsseldorf University Hospital1 trial
• Heinrich-Heine-Universitaet Duesseldorf - Universitaetsklinikum Duesseldorf0 trials
• Heinrich-Heine-Universitaet Duesseldorf - Universitaetsklinikum Duesseldorf (UKD)1 trial
• Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf1 trial
• Universitaetsklinikum Duesseldorf9 trials
• Universitaetsklinikum Duesseldorf AoeR7 trials
• Universitaetsklinikum Duesseldorf AöR6 trials
• Universitaetsklinikum Duesseldorf /ID# 2211690 trials
• Universitaetsklinikum Duesseldorf /ID# 2537110 trials
• Universitaetsklinikum Duesseldorf /ID# 2573070 trials
• Universitaetsklinikum Duesseldorf /ID# 2580780 trials
• Universitaetsklinikum Duesseldorf /ID# 2804091 trial
• Universitaetsklinikum Duesseldorf (Site 0306)1 trial
• Universitaetsklinikum Duesseldorf (Site 0410)1 trial
• Universitaetsklinikum Duesseldorf (Site 0461)1 trial
• Universitaetsklinikum Duesseldorf (Site 0704)0 trials
• Universitaetsklinikum Duesseldorf (Site 1017)0 trials
• Universitaetsklinikum Duesseldorf (Site 1220)1 trial
• Universitaetsklinikum Duesseldorf (Site 1808)1 trial
• Universitaetsklinikum Duesseldorf (Site 2802)1 trial
• Universitaetsklinikum Duesseldorf (Site 4802)1 trial
• Universitaetsklinikum Dusseldorf6 trials
• Universitätsklinikum Düsseldorf51 trials
• Universitätsklinikum Düsseldorf, Frauenheilkunde/Geburtshilfe1 trial
• Universitätsklinikum Düsseldorf, Institut für Allgemeinmedizin (ifam)1 trial
• Universitätsklinikum Düsseldorf, Institut für Diagnostische und Interventionelle Radiologie1 trial
• Universitätsklinikum Düsseldorf, Institut für Klinische Neurowissenschaften und Medizinische Psychologie1 trial
• Universitatsklinikum Dusseldorf, Klink fur Hamatologie, Onkologie und Klinische Immunologie1 trial
• Universitätsklinikum Düsseldorf / Neurologie0 trials
• Universitatsklinikum Dusseldorf (Site 2108)0 trials
• Universitatsklinikum Dusseldorf (University Hospital Dusseldorf)1 trial
• University Hospital Duesseldorf10 trials
• University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology0 trials
• University Hospital Duesseldorf, Heinrich Heine University1 trial
• University Hospital Düsseldorf16 trials
• University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology0 trials
• University Hospital Düsseldorf, Department of Neurology1 trial
• University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology0 trials
• University Hospital Düsseldorf, Radiation Oncology0 trials
• University Hospital of Duesseldorf2 trials
• University Hospital of Düsseldorf1 trial
• Universitätsklinikum Düsseldorf0 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Type 2 diabetes64 works · 1 trial
• Systemic sclerosis (scleroderma)36 works · 1 trial
• Multiple sclerosis32 works · 3 trials
• Aortic aneurysm20 works · 0 trials
• Myelodysplastic syndromes9 works · 4 trials
• Liver cirrhosis8 works · 0 trials
• Neuromyelitis optica (NMOSD)8 works · 0 trials
• Myasthenia gravis7 works · 0 trials
• Dystonia7 works · 4 trials
• Charcot-Marie-Tooth disease4 works · 0 trials
• Polycystic kidney disease4 works · 0 trials
• Friedreich ataxia4 works · 0 trials